Edinburgh Research Explorer

Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling

Research output: Contribution to journalArticle

Standard

Sensitivity to pertuzumab (2C4) in ovarian cancer models : cross-talk with estrogen receptor signaling. / Mullen, Peter; Cameron, David A; Hasmann, Max; Smyth, John F; Langdon, Simon P.

In: Molecular Cancer Therapeutics, Vol. 6, No. 1, 01.2007, p. 93-100.

Research output: Contribution to journalArticle

Harvard

Mullen, P, Cameron, DA, Hasmann, M, Smyth, JF & Langdon, SP 2007, 'Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling', Molecular Cancer Therapeutics, vol. 6, no. 1, pp. 93-100. https://doi.org/10.1158/1535-7163.MCT-06-0401

APA

Mullen, P., Cameron, D. A., Hasmann, M., Smyth, J. F., & Langdon, S. P. (2007). Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling. Molecular Cancer Therapeutics, 6(1), 93-100. https://doi.org/10.1158/1535-7163.MCT-06-0401

Vancouver

Mullen P, Cameron DA, Hasmann M, Smyth JF, Langdon SP. Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling. Molecular Cancer Therapeutics. 2007 Jan;6(1):93-100. https://doi.org/10.1158/1535-7163.MCT-06-0401

Author

Mullen, Peter ; Cameron, David A ; Hasmann, Max ; Smyth, John F ; Langdon, Simon P. / Sensitivity to pertuzumab (2C4) in ovarian cancer models : cross-talk with estrogen receptor signaling. In: Molecular Cancer Therapeutics. 2007 ; Vol. 6, No. 1. pp. 93-100.